Moreover, CD147-knockdown-plus-trastuzumab treatment exhibited greater efficacy in inhibiting HCC1954 tumor growth than trastuzumab or CD147-knockdown treatment alone (Figure 7B). This evidence concerns the gene BSG and neoplasm.